Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.
1. A compound of Formula (1):
a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein:
at least one of the carbon atoms at positions 2 and 8 of Formula (1) is replaced by a silicon atom;
at least one of the methyl groups at positions 3, 4, 5, 5′, 6, 7, and 10 of Formula (1) is replaced by a group chosen from —Si(R) 3 groups, —Si(R)2(OR) groups, and —Si(R)(OR) 2 groups;
at least one of the methylene groups at positions 1, 9, and 12 of Formula (1) is replaced by a group chosen from >Si(R) 2 groups and >Si(R)(OR) groups; and/or
the methine group at position 11 of Formula (1) is replaced by a group chosen from ≡Si(R) groups and ≡Si(OR) groups; and
wherein each R, which may be identical or different, is independently chosen from hydrogen, hydroxyl, and C 1 -C 4 alkyl groups.
2. A compound according to claim 1 , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein at least one of the carbon atoms at positions 2 and 8 of Formula (1) is replaced by a silicon atom.
3. A compound according to claim 1 , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein at least one of the methyl groups at positions 3, 4, 5, 5′, 6, 7, and 10 of Formula (1) is replaced by a group chosen from —Si(R) 3 groups, —Si(R) 2 (OR) groups, and —Si(R)(OR)2 groups.
4. A compound according to claim 1 , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein at least one of the methylene groups at positions 1, 9, and 12 of Formula (1) is replaced by a group chosen from >Si(R) 2 groups and >Si(R)(OR) groups.
5. A compound according to claim 1 , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the methine group at position 11 of Formula (1) is replaced by a group chosen from ≡Si(R) groups and ≡Si(OR) groups.
6. A compound according to claim 1 chosen from Compound (1-1):
and pharmaceutically acceptable salts and deuterated derivatives thereof.
7. A compound according to claim 1 chosen from Compound (1-2):
and pharmaceutically acceptable salts and deuterated derivatives thereof.
8. A compound according to claim 1 chosen from compounds of Formula (1-3), compounds of Formula (1-4), compounds of Formula (1-5), compounds of Formula (1-6), compounds of Formula (1-7), compounds of Formula (1-8), compounds of Formula (1-9), compounds of Formula (1-10), and compounds of Formula (1-11):
wherein each R is independently selected from H, —OH, —O(C 1 -C 4 alkyl), and C 1-4 alkyl groups, and pharmaceutically acceptable salts and deuterated derivatives thereof.
9. A compound according to claim 1 , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein at least one hydrogen atom of at least one R group is replaced by a deuterium atom.
10. A compound according to claim 1 , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each R is independently chosen from C 1 alkyl groups and C2 alkyl groups.
11. A compound according to claim 1 , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each R is independently —CH 3 or —CD 3 .
12. A compound according to claim 1 , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each R is independently —CH 3 .
13. A compound according to claim 1 chosen from compounds of Formulae (1-12) and (1-13):
and pharmaceutically acceptable salts and deuterated derivatives thereof.
14. A compound of Formula (1-14):
or a pharmaceutically acceptable salt or deuterated derivative thereof, wherein R is H, —OH, —O(C 1 -C 4 alkyl), or C 1 -C 4 alkyl groups.
15. A compound according to claim 14 , wherein R is a C 1 -C 4 alkyl group.
16. A pharmaceutical composition comprising:
(a) at least one compound chosen from compounds according to claim 1 , pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing;
(b) at least one pharmaceutically acceptable carrier; and
optionally one or more of:
(c) Compound (II):
a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; and
(d) Compound (III):
a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
17. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition according to claim 16 , pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing.
18. A compound of Formula (2):
or a pharmaceutically acceptable salt or deuterated derivative thereof, wherein:
X is selected from —Si(CH 3 ) 3 ,
Z is selected from
and
wherein each compound of Formula (2) contains at least one Si atom.
19. The compound of claim 18 , wherein the compound is chosen from:
and pharmaceutically acceptable salts and deuterated derivatives thereof.
20. A compound of Formula (3):
or a pharmaceutically acceptable salts or deuterated derivative thereof, wherein:
X is selected from —Ge(CH 3 ) 3 ,
Z is selected from
and
wherein each compound of Formula (3) contains at least one Ge atom.
21. The compound of claim 20 , wherein the compound is chosen from:
and pharmaceutically acceptable salts and deuterated derivatives thereof.
22. A pharmaceutical composition comprising:
(a) at least one compound chosen from compounds of claim 18 ;
(b) at least one pharmaceutically acceptable carrier; and
optionally one or more of:
(c) (i) a compound chosen from Compound (II):
and pharmaceutically acceptable salts and deuterated derivatives thereof; and
(ii) a compound chosen from Compound (III), Compound (III-d):
and pharmaceutically acceptable salts and deuterated derivatives thereof.
23. A pharmaceutical composition comprising a compound of claim 19 and a pharmaceutically acceptable carrier.
24. The pharmaceutical composition of claim 23 , further comprising at least one compound selected from Compound (II):
pharmaceutically acceptable salts thereof.
25. The pharmaceutical composition of claim 24 , wherein the pharmaceutical composition comprises Compound (II) and Compound (III).
26. The pharmaceutical composition of claim 24 , wherein the pharmaceutical composition comprises Compound (II) and Compound (III-d).
27. A pharmaceutical composition comprising a compound of claim 21 and a pharmaceutically acceptable carrier.
28. The pharmaceutical composition of claim 27 , further comprising at least one compound selected from Compound (II):
pharmaceutically acceptable salts thereof.
29. The pharmaceutical composition of claim 28 , wherein the pharmaceutical composition comprises Compound (II) and Compound (III).
30. The pharmaceutical composition of claim 28 , wherein the composition comprises Compound (II) and Compound (III-d).
31. A method of treating cystic fibrosis comprising administering to a patient in need thereof, a pharmaceutical composition according to claim 22 .